Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

NCT ID: NCT03741699

Last Updated: 2024-10-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-18
• Study Completion Date: 2024-05-11

Brief Summary

Controlled ovarian stimulation (COS) is one of the first stages of assisted reproductive treatment. The goal is to mimic the ovarian cycle while stimulating the ovaries to overproduce eggs capable of being fertilized, thus maximizing the chances of reproductive success. The stimulation phase involves the use of different hormonal medications but requires tests to check the development of follicles, and hormonal adjustment to get the optimal ovarian response to stimulation.

However, between 9 to 24% of patients fail to respond adequately to standard stimulation protocols, resulting in Poor Ovarian Response (POR). In addition to the low oocyte production, POR results in a restricted number of good quality embryos with appropriate implantation potential, suggesting a compromised oocyte quality.

POR is one of the most challenging problems in reproductive medicine. Poor responders are difficult to treat since their response to stimulation tend to be deficient even when using different drugs or protocols. In recent years, different therapeutic alternatives have been proposed for these patients. However, to date, the optimal stimulation protocol has not yet been described and oocyte donation is often offered as their only option to achieve pregnancy.

Recently, evidence has emerged that supplementation with a specific hormone, luteinizing hormone (LH), during or prior to COS could lead to improved reproductive outcomes in poor responders by increasing the number of oocytes retrieved and improving their quality.

The present study aims to evaluate the effect of the treatment with LH prior to COS on the ovarian response in patients with POR and advanced maternal age, the worst prognosis but more frequent group of poor responders attending fertility clinics. We will assess whether LH treatment prior to COS increases the number and quality of oocytes retrieved in those patients and, finally, analyse the impact in their chances of getting pregnant and having a baby.

Conditions

Infertility, Female

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1 - experimental group

Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).

Group Type: EXPERIMENTAL

Pre-treatment with rLH (Luveris 75 IU),

Intervention Type: DRUG

Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)

Arm 2 - control (no pre-treatment) group

The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Pre-treatment with rLH (Luveris 75 IU),

Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. -Patients with POR according to specific criteria that are in line with the criteria defined by the ESHRE (Bologna Criteria), according to which a patient is classified as a poor ovarian responder when she meets two of the three of the following criteria: I.- Previous episode of POR (≤3 oocytes) with conventional stimulation protocol II.- Abnormal ovarian reserve test with an antral follicle count (AFC) <5-7 and/or anti-mullerian hormone values (AMH) <0.5-1.1 ng/mL.

III.- Women ≥40 years old and/or who have any other risk factor for POR. In addition, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test.

2. - Women ≥35 to ≤43 years for COS and assisted reproduction techniques (ART).

3. - Couple or single woman, accepting preimplantation genetic diagnosis (PGS) after blastocyst biopsy and delayed transfer for selection of euploid embryos.

4. - Body Mass Index (BMI) between18 and 30 kg/m 2 , inclusive.

5. - Ejaculatory sperm with concentration ≥ 5 mill spermatozoa/mL and ≥ 5 mill total spermatozoa progressive motility. Bank and cryopreserved semen allowed.

6. - Informed consent completed, signed and dated.

Exclusion Criteria

1. - Cases of recurrent spontaneous miscarriage (≥2 clinical miscarriages) or implantation failure (after transfer of 6 good D3 embryos or 4 good blastocysts) will be excluded.

2. - Use of testicular or epididymal spermatozoa as well as ejaculate with concentration < 5 mill spermatozoa/mL and < 5 mill total spermatozoa progressive motility.

3. - Primary ovarian failure, PCOS (in accordance with the Rotterdam criteria) or ovary/s inaccessible for oocyte retrieval.

4. - Anatomical uterine abnormalities and any endometrium or myometrium pathology (adenomyosis, polyps, myoma, etc.) that may interfere with implantation or pregnancy. Patients with previous polypectomy, myomectomy or surgery for septate/subseptate/arcuatus uterus should not be excluded.

5. - Presence of unilateral or bilateral hydrosalpinx that has not been surgically removed or ligated.

6. - Presence of level III-IV endometriosis.

7. - History of tumours in the hypothalamus or pituitary gland, or ovarian, uterine or breast cancer.

8. - Abnormal bleeding of undetermined origin.

9. - Known infection with human immunodeficiency virus, active hepatitis B or C virus in the woman or her partner.

10. - Known allergy or hypersensitivity to the drugs administered during the trial.

11. - Concurrent significant medical pathologies that would endanger the patient's safety (uncontrolled thyroid or adrenal dysfunction, severe hepatic or renal impairment, etc.) or interfere with the test evaluations or the clinical outcomes (i.e. confirmed thrombophilia).

12. - Use of concomitant medication or any other circumstances that, in the opinion of the investigator, interferes with the development of the trial or does not ensure the safety and efficacy of the data.

13. - Simultaneous participation in another clinical trial or previous participation in this study.

14. - Participation in another clinical study two months before inclusion in the present study that could affect its objectives.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 43 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Merck, S.L., Spain

INDUSTRY

Sponsor Role: collaborator

Syntax for Science, S.L

INDUSTRY

Sponsor Role: collaborator

Fundación IVI

OTHER

Sponsor Role: collaborator

Instituto Valenciano de Infertilidad, IVI Alicante

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Manuel Muñoz, Dr.

Role: PRINCIPAL_INVESTIGATOR

Physician - Investigator

Locations

IVI Alicante

Alicante, Valencia, Spain

IVI Madrid

Madrid, , Spain

IVI Murcia

Murcia, , Spain

Countries

Spain

Other Identifiers

2017-004298-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1601-ALC-002-MM

Identifier Type: -

Identifier Source: org_study_id